Evaluating the Use of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19
Official Title: A 5395 A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19
The purpose of this study is to evaluate the ability of hydroxychloroquine (HCQ) and azithromycin (Azithro) compared to placebo (sugar capsule) to prevent hospitalization or death in persons with COVID-19.
You may be eligible for this study if:
- You are symptomatic, outpatient, adult (≥18 years) with SARS-CoV-2 infection
- Have documentation of confirmed active SARS-CoV-2 infection from any respiratory specimen collected <96 hours from when the first dose of study treatment is expected to be taken
- You are experiencing at least one of the following SARS-CoV-2 infection symptoms within 24 hours of screening: fever (can be subjective) OR cough OR shortness of breath
- You agree to not obtain study medications outside of the this study